Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.
Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at ...
Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...
(A, B) Western blotting analysis of FASN and PARP1 expression in stable MDA-MB-436 cells overexpressing FASN (MDA-MB-436/FASN) and MDA-MB-231 cells with FASN knockdown (MDA-MB-231/shFASN) along with ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Ways to accelerate the local implementation and adoption of the homologous recombination deficiency (HRD) testing in India. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
This idea sparked the development of PARP inhibitors – drugs now used to treat tens of thousands of people with BRCA-related cancers, including breast, ovarian, pancreatic and, more recently, prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results